PF679 REAL‐WORLD SAFETY DATA FROM A NONINTERVENTIONAL LONG‐TERM POSTAUTHORIZATION SAFETY STUDY OF RUXOLITINIB IN MYELOFIBROSIS
Fiorenza Barraco(Hôpital Lyon Sud), Heinz Gisslinger(Medical University of Vienna), Robert P. Pack(Novartis (Switzerland)), K. Burock(Bayer (United States)), Richard Greil(Paracelsus Medical University), Raoul Herbrecht(Institut de Cancérologie Strasbourg), Monika Wroclawska(Novartis (Switzerland)), Wolfgang Willenbacher(Universität Innsbruck), Reinier Raymakers(University Medical Center Utrecht), Rüdiger Liersch(Augenstern), Michael P. Levine(Kenyon College), Hendrik B. Schmidt(Praxis für Humangenetik), Andreas Reiter(Heidelberg University)
Cited by 0
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
|Clinical Microbiology and Infection|2018|1.5k